Talk:Methylenedioxybenzylamphetamine

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Psychoactive and Recreational Drugs (defunct)

This article is within the scope of WikiProject Psychoactive and Recreational Drugs, a project which is currently considered to be defunct.Psychoactive and Recreational DrugsWikipedia:WikiProject Psychoactive and Recreational DrugsTemplate:WikiProject Psychoactive and Recreational DrugsPsychoactive and Recreational Drugs articles

Categories and ineffectiveness

Given that it "produces few to no effects", should we really be categorizing it as 'psychedelic' and 'psychoactive'? DS (talk) 14:56, 3 November 2009 (UTC)[reply]

Brass Eye

"In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ."

In fact, Hansard refers specifically to 3,4-Methylenedioxyamphetamine (MDA), sometimes referred to as “sass”...

...but I'll leave any editing to a chemist. 81.105.46.48 (talk) 16:02, 5 November 2024 (UTC)[reply]